{"prompt": "['Novartis', 'Confidential', 'Page 4', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '7', 'Safety monitoring', '54', '7.1', 'Adverse events', '54', '7.2', 'Serious adverse events', '56', '7.2.1', 'Definition of SAE', '56', '7.2.2', 'SAE reporting', '57', '7.3', 'Liver safety monitoring', '57', '7.4', 'Reporting of study treatment errors including misuse/abuse', '58', '7.5', 'Pregnancy reporting', '59', '8', 'Data review and database management', '59', '8.1', 'Site monitoring', '59', '8.2', 'Data collection', '60', '8.3', 'Database management and quality control', '60', '8.4', 'Data Monitoring Committee', '61', '8.5', 'Adjudication Committee', '61', '9', 'Data analysis', '62', '9.1', 'Analysis sets', '62', '9.2', 'Patient demographics and other baseline characteristics', '62', '9.3', 'Treatments', '63', '9.4', 'Analysis of the primary variable', '63', '9.4.1', 'Variables', '63', '9.4.2', 'Statistical model, hypothesis and method of analysis', '63', '9.4.3', 'Handling of missing values/ early discontinuations', '64', '9.4.4', 'Multiplicity Adjustment', '64', '9.4.5', 'Supportive analyses', '65', '9.5', 'Analysis of secondary endpoints', '65', '9.5.1', 'Efficacy variables', '65', '9.5.2', 'Safety variables', '67', '68', '68', '68', '68', '68', '9.7', 'Interim analyses', '71', '9.8', 'Sample size calculation', '71', '10 Ethical considerations', '71', '10.1', 'Regulatory and ethical compliance informed consent procedures', '71']['Novartis', 'Confidential', 'Page 5', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '10.2', 'Informed consent procedures', '72', '10.3', 'Responsibilities of the investigator and IRB/IEC', '72', '10.4', 'Publication of study protocol and results', '72', '10.5', 'Quality Control and Quality Assurance', '72', '11 Protocol adherence', '73', '11.1 Protocol amendments', '73', '12 References', '73', '13 Appendix 1: Liver event and Laboratory trigger Definitions and Follow-up', 'Requirements', '76', '14 Appendix 2: Spirometry Guidance', '78', '15 Appendix 3: Instruction for Use of Conceptl', '81', '16 Appendix 4: Instruction for Use of Accuhaler\u00ae/Diskus\u00ae', '85', '17 Appendix 5: Instructions for Use of the Respimat', '90', '93', '19 Appendix 7: AQLQ-S', '94', '20 Appendix 8: ACQ-7', '99', '101', '22 Appendix 10: Low, medium and high Daily Doses of Inhaled Glucocorticosteroids', 'for Adults\u00b9', '106', 'List of tables', 'Table 2-1', 'Objectives and related endpoints', '17', 'Table 5-1', 'Study Treatments', '34', 'Table 5-2', 'Prohibited asthma-related medications', '36', 'Table 5-3', 'Prohibited Medications', '37', 'Table 5-4', 'Medications allowed under certain conditions', '37', 'Table 5-5', 'Assessments for Patients who Discontinue Study Treatment', '40', 'Table 6-1', 'Assessment schedule', '42', 'Table 6-2', 'Timed Assessments', 'Error! Bookmark not defined.', 'Table 7-1', 'Guidance for capturing the study treatment errors including', 'misuse/abuse', 'Error! Bookmark not defined.', 'Table 13-1', 'Liver Event and Laboratory Trigger Definitions', '76', 'Table 13-2', 'Follow Up Requirements for Liver Events and Laboratory Triggers', '76', 'List of figures', 'Figure 3-1', 'Study design', '20']\n\n###\n\n", "completion": "END"}